Scientists from the CTI Partner Institutions in China travelled to Oxford for the symposium and it provided a great opportunity for the scientists involved to present their results so far and discuss data face-to-face with their collaborators. Additionally, it enabled other researchers from both China and the University of Oxford to learn more about the collaboration and think about future projects. Co-hosted by Chinese Society for Immunology (CSI), British Society for Immunology (BSI), Chinese Academy of Medical Sciences (CAMS), Oxford University, and co-organized by National Key Laboratory of Medical Immunology, the 1st CSI-BSI Joint Symposium on Immunology & the 5th CTI Symposium was held in Shanghai on May 24 to 28th, 2017.
Professor Xuetao Cao’s seminar proved to be a particular highlight of the symposium. He spoke in front of a packed lecture theatre and it was clear from the amount of discussion that his seminar generated, that as well as his role as Director of CAMS he also manages a full and outstanding research program.The second day of the visit allowed the visitors from Chinese Partner Institutions to discover more about research that it is currently happening in Oxford, including presentations by Oxford researchers and a tour of the new NDM Research Building–TDI. A focus of the day was on the future of the project and logistically what would need to be done to expand the collaboration to include more groups.
Although the main focus of the symposium was on the science, the visit provided an ideal opportunity for the University of Oxford to return the hospitality that was shown at the first symposium in China in 2013. On Monday night a dinner was held in Merton College with the Director of the Wellcome Trust, Jeremy Farrar, the MRC Immunology Programme Manager, Georgina Drury and Sir John Bell in attendance. Overall, the symposium helped to strengthen links between China and the University of Oxford, with the hope that this collaboration will continue to benefit all involved for many years to come as well as resulting in new drugs and treatments for patients.